Megan Mendieta

Ms. Megan Mendieta


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MMMegan Mendieta
Megan Mendieta
MEHRDAD BANDEGIMEHRDAD BANDEGI
MEHRDAD BANDEGI
EBEzgi Biltekin
Ezgi Biltekin
Metin AkayMetin Akay
Metin Akay
BOBulent ozpolat
Bulent ozpolat
Metin AkayMetin Akay
Metin Akay
Glioblastoma Multiforme (GBM) is one of the most common brain tumors and is associated with aggressive tumor characteristics and extremely poor patient survival. The median survival time for GBM patients is around 12–15 months. Temozolomide (TMZ) is a key chemotherapeutic drug used in the treatment of GBM. However, at least 50% of GBM patients do not respond to TMZ, necessitating the identification of novel therapeutic strategies sensitizing patients to TMZ. In this study, we aimed to investigate the effects of two different tumor suppressor microRNAs (miR-329 and miR-449b) on cell proliferation and migration of GBM cells, and their potential for sensitizing GBM cells to TMZ. Our findings show that MiR-329/449b treatments suppressed spheroid formation and migration of GBM (LN229 and U87) cells. When miR treatments were combined with Temozolomide (TMZ), we also observed that they synergistically enhanced the suppressive effects of TMZ and inhibited the activity of clinically significant NF-KB and Src/FAK signaling pathways, making the combination therapy a viable option to treat GBM, with greater impact on patient survival.

21 April 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MMMegan Mendieta
Megan Mendieta
MBMehrdad Bandegi
Mehrdad Bandegi
EBEzgi Biltekin
Ezgi Biltekin
Metin AkayMetin Akay
Metin Akay
BOBulent ozpolat
Bulent ozpolat
Metin AkayMetin Akay
Metin Akay
Glioblastoma Multiforme (GBM) is the most common brain tumors that is associated with aggressive tumor characteristics and extremely poor patient survival. The median survival time for GBM patients is around 12-15 months. Temozolomide (TMZ) is a key chemotherapeutic drug used in the treatment of GBM However, at least 50% of GBM patients do not respond to TMZ, necessitating the identification of novel therapeutic strategies sensitizing the patients to TMZ. In this study we aimed to investigate effects of two different tumor suppressor microRNAs (miR-329 and miR-449b) on cell proliferation and migration of GBM cells their potential for sensitizing GBM cells to TMZ. Our findings MiR-329/449b treatments suppressed spheroid formation and migration of GBM (LN229 and U87) cells. When miR treatments were combined with Temozolomide (TMZ) we observed that they synergistically enhanced the suppressive effects of TMZ and inhibited the activity of clinically significant NF-KB Src/FAK signaling pathways making the combination therapy as a viable option to treat GBM with greater impact on patient survival.